scholarly journals Genetic Variation of Migration Inhibitory Factor Gene rs2070766 Is Associated With Acute Coronary Syndromes in Chinese Population

2022 ◽  
Vol 12 ◽  
Author(s):  
Jin-Yu Zhang ◽  
Qian Zhao ◽  
Fen Liu ◽  
De-Yang Li ◽  
Li Men ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Clinical Outcomes ◽  
Migration Inhibitory Factor ◽  
Chinese Population ◽  
Acute Coronary Syndromes ◽  
Multivariate Logistic Regression Analysis ◽  
Inhibitory Factor ◽  
Control Subjects ◽  
Coronary Syndromes

Genetic variation of macrophage migration inhibitory factor (MIF) gene has been linked to coronary artery disease. We investigated an association between the polymorphism of MIF gene rs2070766 and acute coronary syndromes (ACS) and the predictive value of MIF gene variation in clinical outcomes. This study involved in 963 ACS patients and 932 control subjects from a Chinese population. All participants were genotyped for the single nucleotide polymorphism (SNP) of MIF gene rs2070766 using SNPscan™. A nomogram model using MIF genetic variation and clinical variables was established to predict risk of ACS. Major adverse cardiovascular events (MACE) were monitored during a follow-up period. The frequency of rs2070766 GG genotype was higher in ACS patients than in control subjects (6.2 vs 3.8%, p = 0.034). Multivariate logistic regression analysis revealed that individuals with mutant GG genotype had a 1.7-fold higher risk of ACS compared with individuals with CC or CG genotypes. Using MIF rs2070766 genotypes and clinical factors, we developed a nomogram model to predict risk of ACS. The nomogram model had a good discrimination with an area under the curve of 0.781 (95% CI: 0.759–0.804), concordance index of 0.784 (95% CI: 0.762–0.806) and well-fitted calibration. During the follow-up period of 25 months, Kaplan-Meier curves demonstrated that ACS patients carrying GG phenotype developed more MACE compared to CC or CG carriers (p < 0.05). GG genotype of MIF gene rs2070766 was associated with a higher risk of ACS in a Chinese population. The GG genotype carriers in ACS patients had worse clinical outcomes compared with those carrying CC or CG genotype. Together with rs2070766 genetic variant of MIF gene, we established a novel nomogram model that can provide individualized prediction for ACS.

scholarly journals Macrophage Migration Inhibitory Factor Is Enhanced in Acute Coronary Syndromes and Is Associated with the Inflammatory Response

PLoS ONE ◽  
2012 ◽  
Vol 7 (6) ◽  
pp. e38376 ◽  
Author(s):  
Iris I. Müller ◽  
Karin A. L. Müller ◽  
Heiko Schönleber ◽  
Athanasios Karathanos ◽  
Martina Schneider ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Migration Inhibitory Factor ◽  
Acute Coronary Syndromes ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Macrophage Migration ◽  
Coronary Syndromes

The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study

2018 ◽  
Vol 32 (5) ◽  
pp. 435-442 ◽  
Author(s):  
Jose C. Nicolau ◽  
Remo H. M. Furtado ◽  
Luciano M. Baracioli ◽  
Livia M. Lara ◽  
Talia F. Dalçóquio ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Acute Coronary Syndromes ◽  
Beta Blockers ◽  
St Segment Elevation ◽  
Follow Up Study ◽  
St Segment ◽  
Long Term Follow Up ◽  
Coronary Syndromes

Temporal Changes in Pollen Grain Concentration Predict Short-Term Clinical Outcomes in Acute Coronary Syndromes

2021 ◽  
Vol 30 ◽  
pp. S112
Author(s):  
O. Al-mukhtar ◽  
S. Vogrin ◽  
S. Noaman ◽  
E. Lampugnani ◽  
D. Dinh ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Acute Coronary Syndromes ◽  
Temporal Changes ◽  
Pollen Grain ◽  
Short Term ◽  
Coronary Syndromes

Abstract 3553: Effect of Resolution of Metabolic Syndrome on Endothelial Function and Cardiovascular Events after Acute Coronary Syndromes

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Shin-ichiro Miyazaki ◽  
Yoshikazu Hiasa ◽  
Takefumi Takahashi ◽  
Riyo Ogura ◽  
Naoki Suzuki ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Endothelial Function ◽  
Logistic Regression Analysis ◽  
Acute Coronary Syndromes ◽  
Cardiovascular Events ◽  
Multivariate Logistic Regression Analysis ◽  
Multivariate Logistic Regression ◽  
Coronary Syndromes

Background: Metabolic syndrome (MetS) is associated with endothelial dysfunction, and recognized as a risk factor of cardiovascular events after acute coronary syndromes (ACS). We examined whether the resolution of MetS would improve endothelial function and provide a beneficial effect on clinical outcome after ACS. Methods: We studied 60 patients with MetS who underwent a percutaneous revascularization procedure for ACS. MetS was defined using modified International Diabetes Federation criteria. Brachial artery flow-mediated dilation (FMD) and several risk parameters related to metabolic disorders were assessed at baseline and at 6 months. Each patient was given basic spoken advice on lifestyle modification and optimal medications before discharge. Patients were divided into 2 groups according to whether the criteria for MetS were fulfilled at 6 months: resolved MetS (R-MetS, n=35) and persistent MetS (P-MetS, n=25). Cardiovascular events were defined as cardiac death, stroke, myocardial infarction, unstable angina, and target vessel revascularization. Results: During the 1-year follow-up, 3 patients with R-MetS (8.6%) and 14 patients with P-MetS (56%) had cardiovascular events (p=0.0002). The extent of improvement in FMD was significantly greater in patients with R-MetS than those with P-MetS (change in FMD: 1.5 vs −1.2: p=0.007; respectively). In a multivariate logistic regression analysis, P-MetS was an independent predictor of cardiovascular events (odds ratio 18.4, 95%CI 1.67–28.5, p=0.025). Conclusion: The resolution of MetS is associated with the recovery of endothelial function and prevents cardiovascular events after ACS. Multivariate logistic regression analysis

Abstract 15408: Long-term Antithrombotic Management Patterns After Acute Coronary Syndromes: 2-[[Unsupported Character - Codename ­]]years Follow-up in the EPICOR Asia Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Yong Huo ◽  
Stephen W Lee ◽  
Jitendra P Sawhney ◽  
Hyo-Soo Kim ◽  
Rungroj Krittayaphong ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Hospital Discharge ◽  
Acute Coronary Syndromes ◽  
Single Agent ◽  
Real Life ◽  
Post Discharge ◽  
Index Event ◽  
Coronary Syndromes ◽  
Antithrombotic Management

Introduction: Guidelines recommend dual-antiplatelet therapy (DAPT) for 12 months in patients with acute coronary syndromes (ACS). Information on patterns and duration of DAPT use after hospital discharge in ACS patients in Asia is sparse. Objective: We describe changes in real-life antithrombotic management patterns (AMPs) up to 2-y post discharge based on data from the EPICOR Asia study (NCT01361386). Methods: This observational study enrolled 12 922 hospital survivors post ACS from 218 hospitals in 8 countries/regions in Asia. Data were collected from symptom onset for the index event (ST-segment elevation myocardial infarction [STEMI] 51.2%, non-STEMI (NSTEMI) 19.9%, or unstable angina [UA] 28.9%), during hospitalization, at discharge and over 2 y follow-up. Results: Overall, 90.6% of patients were on DAPT at hospital discharge which declined to 79.6%, 71.8%, 53.7%, and 45.6% at 6, 12, 18, and 23 months post discharge (Fig). At discharge, most patients (87.6%) received aspirin + clopidogrel, with 79.5%, 71.8%, 53.6%, and 45.4% on this combination at 6, 12, 18, and 23 months. At discharge only 3.0% of patients received aspirin + prasugrel and 1.7% of patients received aspirin + cilostazol. Only 8.3% of patients were on single antiplatelet therapy (SAPT) at discharge with 12.2%, 15.6%, 28.1%, and 30.3% on SAPT at 6, 12, 18, and 23 months post discharge; aspirin being the most commonly used single agent. No notable differences were seen among index event groups. Of the patients on DAPT at discharge, STEMI 93.4%; NSTEMI 90.2%; UA 85.9%, comparable proportions across groups remained on DAPT at 23 months follow up; STEMI 51.0%; NSTEMI 51.9%; UA 47.6%. Conclusions: Most ACS patients remain on DAPT at 12 months and around half remain at 23 months post-discharge. Further study should assess between-country differences, the benefit/risk balance from prolonged DAPT, why DAPT is discontinued before 12 months, and impact on clinical outcomes.

Abstract 18945: Baseline Myocardium At-Risk Predicts Subsequent Myocardial Injury in Non ST-Segment Elevation Acute Coronary Syndrome

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Henry Chang ◽  
Jennifer A Dickerson ◽  
David Verhaert ◽  
Orlando P Simonetti ◽  
Giuseppe Ambrosio ◽  
...  
Keyword(s):  
At Risk ◽  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Acute Coronary Syndromes ◽  
Myocardial Injury ◽  
Coronary Syndrome ◽  
St Segment ◽  
Coronary Syndromes ◽  
Myocardium At Risk

BACKGROUND: Increased myocardial injury visualized by late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) portends worse outcomes in patients with acute coronary syndromes (ACS). Although non ST-segment acute coronary syndromes (NSTE-ACS) comprise 70% of all ACS and 1-year mortality rates are similar to the more readily-diagnosed and uniformly-treated ST-elevation myocardial infarction, ischemic changes and treatment strategies in NSTE-ACS are not well-defined, Studies have shown that T2-weighted (T2W) cardiac magnetic resonance (CMR) may be a marker of acute myocardial injury in ACS. We hypothesized that the presence of at-risk myocardium, identified by T2W CMR at presentation, predicts increased subsequent myocardial injury by LGE beyond traditional risk predictors in NSTE-ACS. METHODS & RESULTS: 48 patients enrolled in a prospective study of NSTE-ACS underwent CMR with short tau inversion recovery (T2W STIR) imaging and LGE prior to intervention and repeat CMR 61 ± 27 days later. Baseline presence/absence of increased myocardial signal intensity by T2W STIR was determined by consensus of two expert reviewers blinded to other data. In 13 patients (27%), follow-up LGE images showed more extensive injury compared to baseline. Peak troponin at time of event, baseline TIMI risk score and baseline LGE score did not predict subsequent LGE score increase (p=0.13, p=0.48, p=0.55, respectively). Conversely, a much higher proportion of patients with vs. without increased T2W STIR SI at baseline demonstrated increased myocardial injury by LGE at follow-up (12/31 vs. 1/17, p<0.01; Figure). CONCLUSION: Myocardium at-risk by T2-weighted STIR CMR in patients with NSTE-ACS predicts subsequent myocardial injury, more so than clinical predictors or extent of baseline myocardial damage. Prospective studies that intensify care for patients with at-risk myocardium may help identify strategies to improve myocardial salvage and reduce mortality in NSTE-ACS.

Sign in / Sign up

Export Citation Format

Share Document